We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck KGaA (MKGAF) Q3 Earnings Down Y/Y, Sales Flat
Read MoreHide Full Article
Merck KGaA (MKGAF - Free Report) is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.
The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.
The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.
At its 2016 Capital Market Day, the company provided an update on its objectives up to 2018. Beginning 2017, the company aims to gain approval of one medicine or new indication every year.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: The company’s third-quarter 2017 earnings per American Depositary Receipt (ADR) came in at $1.77, compared to the year-ago figure of $1.90.
Revenue: The company posted revenues of $4.35 billion in the reported quarter. The Healthcare and Life Science segment drove the company’s organic growth.
Key Stats: The company’s multiple sclerosis therapy, Mavenclad, received recommendation from NICE for approval in UK. Bavencio received approval in the EU and Japan for treating metastatic Merkel cell carcinoma in late September. Moreover, Merck completed the divestment of its Biosimilars business to Fresenius as a part of its strategy to become a leading science and technology company.
Guidance Reiterated: For 2017, the company maintained its net sales forecast in the range of €15.3 billion – €15.7 billion. The company expects net sales to be at the lower end of the expected range due to appreciating Euro. The company reiterated its earnings per share forecast in the range of €6.15 - €6.50.
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Merck KGaA (MKGAF) Q3 Earnings Down Y/Y, Sales Flat
Merck KGaA (MKGAF - Free Report) is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.
The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.
The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.
At its 2016 Capital Market Day, the company provided an update on its objectives up to 2018. Beginning 2017, the company aims to gain approval of one medicine or new indication every year.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: The company’s third-quarter 2017 earnings per American Depositary Receipt (ADR) came in at $1.77, compared to the year-ago figure of $1.90.
Revenue: The company posted revenues of $4.35 billion in the reported quarter. The Healthcare and Life Science segment drove the company’s organic growth.
Key Stats: The company’s multiple sclerosis therapy, Mavenclad, received recommendation from NICE for approval in UK. Bavencio received approval in the EU and Japan for treating metastatic Merkel cell carcinoma in late September. Moreover, Merck completed the divestment of its Biosimilars business to Fresenius as a part of its strategy to become a leading science and technology company.
Guidance Reiterated: For 2017, the company maintained its net sales forecast in the range of €15.3 billion – €15.7 billion. The company expects net sales to be at the lower end of the expected range due to appreciating Euro. The company reiterated its earnings per share forecast in the range of €6.15 - €6.50.
Merck KGaA Price and EPS Surprise
Merck KGaA Price and EPS Surprise | Merck KGaA Quote
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>